An interventional study of RENEW in Axial Spondyloarthritis, sponsored by University of Michigan. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by University of Michigan · Not applicable, Interventional, and Other
The researchers are testing a web-based peer-led program to help manage energy and symptoms in people who have axial spondyloarthritis (axSpA). There are 3 main reasons the researchers are doing this study: 1) to test how easy it is for people with spondyloarthritis to use the RENEW program; 2) to assess whether people like the RENEW program and 3) to understand if it helps with symptom management and disease burden.
186 studies on the registry are indexed under Axial Spondyloarthritis; 57 are open to participants now.
This study's planned enrollment of 40 is below the median of 108 across 122 interventional studies indexed under Axial Spondyloarthritis.
Browse Axial Spondyloarthritis studies →University of Michigan is the lead sponsor of 1,506 studies on the registry; 192 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 133 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants placed in this group will be assigned a peer health coach to help guide them through the RENEW program right away. Peer health coaches are people on the study team with spondyloarthritis. In addition, approximately 10 to 15 people from this group will be invited to take part in an optional 30-minute interview after the program ends, to share feedback about their experience with RENEW. If invited, participating in this interview is entirely voluntary.
Other: RENEW
If placed in this group, participants will receive access to the RENEW website at the end of the 12-week study period. At the end of the 12 weeks, participants will be offered the option to have 1 peer health coaching session with a peer health coach.
RENEW is a 12-week, peer-led, web-based program to help people with spondyloarthritis learn skills that can be used to manage disease symptoms and improve well-being. It includes: A website that includes information, worksheets, tools, and information from other people with spondyloarthritis 9 calls with a peer health coach, beginning with weekly calls for the first 6 weeks, and every other week for the last 6 weeks of the program. We will use telehealth platforms (like Zoom) for these calls. We will record them so we can track how well the peer health coaches are following the program. Each call will last no more than 30 minutes.
attendance at peer health coaching sessions among RENEW intervention participants.
Assessed using the Goal Attainment Scaling (GAS) method, which measures the extent to which participants achieved their individualized goals
Time frame: across the 12-week period
Goal Attainment Scaling (GAS)
Assessed by health coach
Time frame: Weeks 0, 6, 12
Theoretical Framework of Acceptability (TFA) score (RENEW Intervention group)
12-item measure assessing affective attitude, burden, perceived effectiveness, and self-efficacy. An average of item scores \>4 out of 5 has been established as indicating high acceptability.
Time frame: Week 12
Qualitative Interviews (n=10-15 of RENEW Intervention group)
Acceptability will also be assessed through qualitative interviews with a subset of intervention participants.
Time frame: Week 12
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Mar 2027, 5 months after the start.
Of 45 non-industry interventional studies with no phase under Axial Spondyloarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's planned 5 months is below that.
Counting every sponsor, half of 45 studies reached it within 28 months; a quarter within 11 and three quarters within 42.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.